Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Pfizer begins study of oral drug for prevention of COVID-19

09/27/2021 | 07:19am EDT

Sept 27 (Reuters) - Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.

The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG , have been racing to develop an easy-to-administer antiviral pill for COVID-19.

The mid-to-late-stage study will test Pfizer's drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.

In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

To date, Gilead Sciences Inc's intravenous drug remdesivir is the only approved antiviral treatment for COVID-19 in the United States.

Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.

Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the COVID-19 infection.

Molnupiravir is also being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

(Reporting by Manojna Maddipatla and Amruta Khandekar in Bengaluru; Editing by Krishna Chandra Eluri)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 0.97% 66.525 Delayed Quote.13.11%
ROCHE HOLDING AG -1.69% 357.75 Delayed Quote.17.78%
All news about GILEAD SCIENCES, INC.
11:10aAtea plunges after COVID-19 treatment fails to help patients in study
RE
09:52aGILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
MT
08:32aGILEAD SCIENCES : Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis..
BU
05:06aGILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
AQ
10/18GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
MT
10/18GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
BU
10/18Gilead Says FDA Approves Expanded Indication of Biktarvy for Treatment of HIV-1 in Pedi..
DJ
10/15GILEAD SCIENCES : Says Breast Cancer Therapy Receives Positive Opinion by European Medicin..
MT
10/15GILEAD SCIENCES : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for..
BU
10/15Gilead's Sacituzumab Govitecan Gets Positive CHMP Opinion in Breast Cancer
DJ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 103 M - -
Net income 2021 6 563 M - -
Net Debt 2021 23 120 M - -
P/E ratio 2021 13,0x
Yield 2021 4,28%
Capitalization 82 626 M 82 626 M -
EV / Sales 2021 4,21x
EV / Sales 2022 4,15x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 65,90 $
Average target price 76,35 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.13.11%82 626
WUXI APPTEC CO., LTD.28.00%65 873
BIONTECH SE220.28%63 059
REGENERON PHARMACEUTICALS12.50%56 504
VERTEX PHARMACEUTICALS-23.50%46 905
BEIGENE, LTD.39.64%33 674